These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

490 related items for PubMed ID: 16372821

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL, Figgitt DP.
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors.
    Jaakkola T, Laitila J, Neuvonen PJ, Backman JT.
    Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):44-51. PubMed ID: 16867170
    [Abstract] [Full Text] [Related]

  • 10. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance.
    Wang B, Wang J, Huang SQ, Su HH, Zhou SF.
    Curr Drug Metab; 2009 Sep; 10(7):781-834. PubMed ID: 19925388
    [Abstract] [Full Text] [Related]

  • 11. Clinical consequences of cytochrome P450 2C9 polymorphisms.
    Kirchheiner J, Brockmöller J.
    Clin Pharmacol Ther; 2005 Jan; 77(1):1-16. PubMed ID: 15637526
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.
    Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivistö KT.
    Clin Pharmacol Ther; 2002 Sep; 72(3):326-32. PubMed ID: 12235454
    [Abstract] [Full Text] [Related]

  • 14. Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development.
    He SM, Zhou ZW, Li XT, Zhou SF.
    Curr Med Chem; 2011 Sep; 18(5):667-713. PubMed ID: 21182487
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers.
    Cheng Y, Wang G, Zhang W, Fan L, Chen Y, Zhou HH.
    Eur J Clin Pharmacol; 2013 Mar; 69(3):407-13. PubMed ID: 22842957
    [Abstract] [Full Text] [Related]

  • 17. Drug interactions of clinical importance with antihyperglycaemic agents: an update.
    Scheen AJ.
    Drug Saf; 2005 Mar; 28(7):601-31. PubMed ID: 15963007
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide.
    Vormfelde SV, Engelhardt S, Zirk A, Meineke I, Tuchen F, Kirchheiner J, Brockmöller J.
    Clin Pharmacol Ther; 2004 Dec; 76(6):557-66. PubMed ID: 15592327
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.